Europe Anti-Nuclear Antibody Test Market is expected to reach USD 491.05 million by 2025, from USD 268.98 million in 2017 growing at a CAGR of 7.9% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.
Request Sample Report at: – https://databridgemarketresearch.com/request-a-sample/?dbmr=europe-anti-nuclear-antibody-test-market
Market Segmentation: Europe Anti-Nuclear Antibody Test Market
The Europe anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the EU anti-nuclear antibody test market with 59.2% market share and is expected to reach USD 294.67 million by 2025, with the highest CAGR of 8.1% in the forecast period 2018 to 2025.
• The Europe anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, indirect immunofluorescence is expected to dominate the EU anti-nuclear antibody test market with 59.9% market share and is expected to reach USD 284.10 million by 2025, with the CAGR of 7.4% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 9.2% in the forecast period, and is expected to reach USD 82.42 million in 2025 from USD 41.21 million in 2017.
• The Europe anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, systemic lupus erythematosus is expected to dominate the EU anti-nuclear antibody test market with 51.3% market share and is expected to reach USD 256.05 million by 2025, with the highest CAGR of 8.2% in the forecast period 2018 to 2025.
• The Europe anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the EU anti-nuclear antibody test market with 60.3% market share and is expected to reach USD 299.43 million by 2025, with the highest CAGR of 8.1% in the forecast period 2018 to 2025.
Any customization required or has any query? Ask to our industry expert: – https://databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-anti-nuclear-antibody-test-market
Key Drivers: Europe Anti-Nuclear Antibody Test Market
The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.
On the other hand, strict regulation for product approval is hampering the growth of the market.
Key Points: Europe Anti-Nuclear Antibody Test Market
In 2017, the Europe anti-nuclear antibody test market is dominated by Alere, Inc., followed by Bio-Rad Laboratories and ThermoFisher Scientific, Inc.
• Assay Kits & Reagents is dominating the Europe anti-nuclear antibody test market.
• K. is dominating the EU anti-nuclear antibody test market in the forecast period 2018 to 2025.
For more information about this report visit @ https://databridgemarketresearch.com/reports/europe-anti-nuclear-antibody-test-market/
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]